Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1358894 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1358894 (Open-label, Randomised, Two-way Cross-over)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 1358894 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Sep 2020 Results evaluating safety and pharmacokinetics of oral BI 1358894 in healthy male volunteers, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 6 Feb 2019 to 15 Feb 2019.